Title:Stem Cells Reprogramming in Diabetes Mellitus and Diabetic Complications: Recent Advances
Volume: 20
Author(s): Hafez R Madkor, Mostafa K. Abd El-Aziz, Mostafa S. Abd El-Maksoud, Islam M. Ibrahim and Fares E.M Ali*
Affiliation:
- Department of Pharmacology & Toxicology, Faculty of
Pharmacy, Al-Azhar University, Assiut Branch, Assiut, Egypt 71524
Keywords:
Diabetes mellitus, Stem cells therapy, Reprogramming, Diabetes complications
Abstract: Background: The incidence of diabetes mellitus (DM) is dramatically increasing
worldwide, and it is expected to affect 700 million cases by 2045. Diabetes influences health care
economics, human quality of life, morbidity, and mortality, which were primarily seen extensively in developing countries. Uncontrolled DM, which results in consistent hyperglycemia, may
lead to severe life-threatening complications such as nephropathy, retinopathy, neuropathy, and
cardiovascular complications.
Methodology: In addition to traditional therapies with insulin and oral anti-diabetics, researchers
have developed new approaches for treatment, including stem cell (SC) therapy, which exhibits
promising outcomes. Besides its significant role in treating type one DM (T1DM) and type two
DM (T2DM), it can also attenuate diabetic complications. Furthermore, the development of insulin-producing cells can be achieved by using the different types of SCs, such as embryonic stem
cells (ESCs), induced pluripotent stem cells (iPSCs), and multiple types of adult stem cells, such
as pancreatic, hepatic, and mesenchymal stem cells (MSC). All these types have been extensively
studied and proved their ability to develop insulin-producing cells, but every type has limitations.
Conclusion: This review aims to enlighten researchers about recent advances in stem cell research and their potential benefits in DM and diabetic complications
